Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05169515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05169515 · ClinicalTrials.gov record · last posted 2026-08-17

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Name: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma — clinical trial record (NCT05169515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorHoffmann-La Roche

Started2022-10-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

Protocol amendment history 3 changes detected by DataLookout

2026-08-18

Primary completion moved earlier: 2029-09-15 → 2029-08-05

2026-08-18

Completion moved earlier: 2029-09-15 → 2029-08-05

2026-08-11

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT05169515
Lead Sponsor	Hoffmann-La Roche
Conditions	Non-Hodgkin Lymphoma
Enrollment	121 participants
Start Date	2022-10-26
Primary Completion	2029-08-05 (estimated)
Study Completion	2029-08-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-17